Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Peking University Cancer Hospital & Institute
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07381543CT.gov Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone | — | Not Yet Recruiting | — | — | — |
NCT07398560CT.gov Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study | — | Not Yet Recruiting | — | — | — |
NCT07357532CT.gov Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD | — | Not Yet Recruiting | — | — | — |
NCT07434518CT.gov A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC | — | Recruiting | — | — | — |
NCT07200154CT.gov Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC | — | Not Yet Recruiting | — | — | — |
NCT07173244CT.gov A Real-world Study of Adebrelimab-based Combination Regimens in the Treatment of Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT07069270CT.gov A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy | — | Not Yet Recruiting | — | — | — |
NCT07141264CT.gov Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy | — | Recruiting | — | — | — |
NCT07063407CT.gov Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06914050CT.gov Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy | — | Not Yet Recruiting | — | — | — |
Show 26 more trialsShow fewer
NCT06853678CT.gov Second-line Immunotherapy for ES-SCLC | — | Recruiting | — | — | — |
NCT06869239CT.gov Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy | — | Recruiting | — | — | — |
NCT06614621CT.gov A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06784206CT.gov Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06786312CT.gov A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06739928CT.gov Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC | — | Recruiting | — | — | — |
NCT06610734CT.gov Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) | — | Recruiting | — | — | — |
NCT06672133CT.gov Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC | — | Not Yet Recruiting | — | — | — |
NCT06597513CT.gov Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC | — | Not Yet Recruiting | — | — | — |
NCT06052423CT.gov ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT06773156CT.gov Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer | — | Enrolling By Invitation | — | — | — |
NCT06526624CT.gov A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06480864CT.gov Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06530797CT.gov A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06562920CT.gov Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06498479CT.gov ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06485544CT.gov Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial | — | Recruiting | — | — | — |
NCT06527898CT.gov Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer | — | Recruiting | — | — | — |
NCT06483282CT.gov A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06475209CT.gov Adebrelimab + Apatinib in SCLC Maintenance Therapy | — | Recruiting | — | — | — |
NCT06332950CT.gov Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy | — | Not Yet Recruiting | — | — | — |
NCT06323265CT.gov A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT06306560CT.gov A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC. | — | Not Yet Recruiting | — | — | — |
NCT06267170CT.gov A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT06236997CT.gov Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06177925CT.gov A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adebrelimab (this asset) | Peking University Cancer Hospital & Institute | P3 | BB · 64 |
| Benmelstobart | Yayi He | P4 | A |
| Berzosertib | National Cancer Institute (NCI) | P2 | BBB |
| Anti-Pd-L1 Monoclonal Antibody Shr-1316 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BBB |
| Etoposide | Sichuan University | P4 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Carboplatin | University of Maryland, Baltimore | P4 | BB |
| Veliparib | Central European Society for Anticancer Drug Research | P2 | BB |
| hs-20093 | Shanghai Hansoh Biomedical Co., Ltd | P3 | BB |
+42 more in the Small Cell Lung Carcinoma cohort
Other indications for Adebrelimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P4 | BB · 67 |
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 66 |
| Malignant Pancreatic Neoplasm | — | P2 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adebrelimab in Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adebrelimab-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →